KTTA

Rating neutralTentativeAI Memo

Pasithea Therapeutics

As of 2026-10-09/Confidence medium

Open ticker Back to Memos

Data freshness

AI Memo

As of 2026-10-09 • Model: RankAlpha Sentiment Codex

Decision Panel

Action, confidence, horizon, and decision blockers at a glance.

Report quality notice

small-cap biotech peer set is too weak or includes unrelated comparators for a standard-conviction report

Action

neutral

Confidence

medium

Horizon

—

Key catalyst

PAS-004 advanced-cancer data at ESMO • 2026-10-23

Base target: $0 / p=45% prob

Biggest risk

Small, early-stage datasets may not establish efficacy; weaker or ambiguous NF1 data could sharply reduce confidence in the lead program. Approved NF1-PN MEK inhibitors also set a clinical benchmark. Rising R&D spending and eventual financing needs add dilution risk. [#10-Q-2026-08-14] SEC filing.

Invalidation

Break below $0 or thesis failure.

What would change my mind?

Two dated PAS-004 presentations could strengthen the case for further development if safety, exposure and early clinical signals remain persuasive. June advanced-cancer observations were preliminary and company-reported. [#IR-2026-06-30] Company update.

Research note

Recommendation

neutral

Confidence

medium

As of

2026-10-09

Base target

p=45%

Bull target

p=25%

Bear target

p=30%

Key bullets

Fast scan of bull, bear, and watch items

BullKey bullets

Development spending and future capital needs
Two dated PAS-004 presentations could strengthen the case for further development if safety, exposure and early clinical signals remain persuasive.
June advanced-cancer observations were preliminary and company-reported.

BearKey bullets

The November NF1 presentations are initial Part A data; clinical benefit, durability and registrational relevance remain unproven.
The September 16 8-K concerned expiration and delisting of KTTAW warrants, not delisting of KTTA common stock.
[#8-K-2026-09-16] SEC filing.

WatchKey bullets

PAS-004 advanced-cancer data at ESMO

Summary

High-level snapshot

Recommendation

neutral

Model confidence

medium

Timeframe

Asset

Equity

Trigger

Base case: $0 (p=45%)

Target spread vs base: +92% / -44%

Scenario probabilities

Bull Target: $1 (p=25%)Base Target: $0 (p=45%)Bear Target: $0 (p=30%)

Commentary

The packet has no recent-news, social, options, short-interest or analyst-revision coverage; zero sentiment fields denote unavailable measures, not neutral readings. The dated company presentations improve catalyst visibility versus the prior monitoring view, but the deterministic prior remains negative and clinical outcomes are highly uncertain. No verified post-announcement price-reaction evidence is available.

As of 2026-10-09 • Updated bi-weekly / post-earningsSource: Internal modelMethodology

Analyst Summary

Thesis highlights from the latest analysis

Bull Case

Bear Case

Drivers

Scannable catalysts and supporting factors

Development spending and future capital needs

Scenarios

Bull Target (Scenario probability)

$1 / p=25% prob

Base Target (Scenario probability)

$0 / p=45% prob

Bear Target (Scenario probability)

$0 / p=30% prob

Analysis 2026-10-09 · RankAlpha Sentiment Codex

Analysis reference price unavailable. Targets are shown without scenario returns.

Sentiment & Exposure

News Sentiment (30d)

0.00

Social Sentiment (7d)

0.00

Events

Other notable items detected

EVENT2026-10-23
PAS-004 advanced-cancer data at ESMO
Pasithea plans to present Phase 1 safety and pharmacokinetic data on October 23. The full abstract has not yet been released; the presentation may clarify whether earlier observations hold in a larger dataset. [#IR-2026-07-21] Company announcement.
Prob 85.00% • Move 20.00% • Priced-in 40.00%
EVENT2026-11-13
First public adult NF1 Part A clinical data
Pasithea scheduled cutaneous-neurofibroma and plexiform-neurofibroma presentations for November 12–13. These are initial Phase 1/1b data, not a registrational efficacy readout. [#IR-2026-09-14] Company announcement.
Prob 85.00% • Move 35.00% • Priced-in 30.00%

Short-term Catalysts

Next few weeks

No short-term catalysts

Long-term Catalysts

Months to a year

Development spending and future capital needs
2027-08-14
The June 2026 10-Q reported $45.7 million of cash and cash equivalents and $9.5 million of first-half operating cash use. Management expected funding for at least 12 months from the filing but said significant additional funds would eventually be needed. The date is an estimated reassessment point, not a scheduled financing. [#10-Q-2026-08-14] SEC filing.
Prob 70% • Move -15% • Priced-in 45%

Risks

The November NF1 presentations are initial Part A data; clinical benefit, durability and registrational relevance remain unproven.
The September 16 8-K concerned expiration and delisting of KTTAW warrants, not delisting of KTTA common stock. [#8-K-2026-09-16] SEC filing.
The advanced-cancer data are from an early, heterogeneous study; earlier stable-disease observations do not establish comparative efficacy. [#IR-2026-06-30]
The company expects continued operating losses and additional capital needs despite its reported cash runway. [#10-Q-2026-08-14]

Peers

Symbol	Summary
AZN	Direct adult NF1-associated plexiform-neurofibroma treatment comparator: AstraZeneca's approved MEK inhibitor Koselugo provides a relevant clinical benchmark, but AstraZeneca's diversified valuation is not comparable with Pasithea's. AstraZeneca announcement.

Sources

Internal and external references used in this analysis

Model source: RankAlpha Sentiment Codex
Analysis date: 2026-10-09

Loading AI feed…

Symbol

Summary

AZN

Direct adult NF1-associated plexiform-neurofibroma treatment comparator: AstraZeneca's approved MEK inhibitor Koselugo provides a relevant clinical benchmark, but AstraZeneca's diversified valuation is not comparable with Pasithea's. AstraZeneca announcement.